Secretory leukocyte protease inhibitor expression in various types of gastritis: A specific role of Helicobacter pylori infection

I. Hritz, Doerthe Kuester, Michael Vieth, L. Herszényi, Manfred Stolte, Albert Roessner, Z. Tulassay, Thomas Wex, Peter Malfertheiner

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Objectives: Secretory leukocyte protease inhibitor (SLPI) represents a multifunctional protein of the gastrointestinal mucosa exerting antimicrobial and anti-inflammatory effects. SLPI expression is generally induced during inflammation; however, Helicobacter pylori-meditated gastritis is associated with significantly decreased antral SLPI levels. The aim of the study was to investigate whether SLPI downregulation of gastric mucosa represents a specific phenomenon of H. pylori infection or is generally linked to gastric inflammation. Methods: SLPI expression was retrospectively analysed by immunohistochemistry in 85 paraffin-embedded samples: H. pylori-induced (n = 13), non-steroidal anti-inflammatory drug (NSAID)-enhanced (n = 18), autoimmune (n = 11), lymphocytic gastritis (n = 26) and H. pylori-negative controls (n = 17). The intensity of the staining was semiquantitatively analysed using an immunoreactivity score. Statistical analysis of differences was performed using an analysis of variance test. Results: In comparison with the control group, the SLPI expression of antral mucosa in H. pylori-mediated and lymphocytic gastritis was significantly lower (P

Original languageEnglish
Pages (from-to)277-282
Number of pages6
JournalEuropean Journal of Gastroenterology and Hepatology
Volume18
Issue number3
DOIs
Publication statusPublished - Mar 2006

Fingerprint

Secretory Leukocyte Peptidase Inhibitor
Helicobacter Infections
Gastritis
Helicobacter pylori
Mucous Membrane
Anti-Inflammatory Agents
Inflammation
Gastric Mucosa
Paraffin
Stomach
Analysis of Variance
Down-Regulation
Immunohistochemistry
Staining and Labeling
Control Groups
Pharmaceutical Preparations

Keywords

  • Autoimmune gastritis
  • Gastritis
  • Helicobacter pylori
  • Non-steroidal anti-inflammatory drug
  • Secretory leukocyte protease inhibitor

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Secretory leukocyte protease inhibitor expression in various types of gastritis : A specific role of Helicobacter pylori infection. / Hritz, I.; Kuester, Doerthe; Vieth, Michael; Herszényi, L.; Stolte, Manfred; Roessner, Albert; Tulassay, Z.; Wex, Thomas; Malfertheiner, Peter.

In: European Journal of Gastroenterology and Hepatology, Vol. 18, No. 3, 03.2006, p. 277-282.

Research output: Contribution to journalArticle

Hritz, I. ; Kuester, Doerthe ; Vieth, Michael ; Herszényi, L. ; Stolte, Manfred ; Roessner, Albert ; Tulassay, Z. ; Wex, Thomas ; Malfertheiner, Peter. / Secretory leukocyte protease inhibitor expression in various types of gastritis : A specific role of Helicobacter pylori infection. In: European Journal of Gastroenterology and Hepatology. 2006 ; Vol. 18, No. 3. pp. 277-282.
@article{bfd9eda66eca4f1d9a438b25366b6f6e,
title = "Secretory leukocyte protease inhibitor expression in various types of gastritis: A specific role of Helicobacter pylori infection",
abstract = "Objectives: Secretory leukocyte protease inhibitor (SLPI) represents a multifunctional protein of the gastrointestinal mucosa exerting antimicrobial and anti-inflammatory effects. SLPI expression is generally induced during inflammation; however, Helicobacter pylori-meditated gastritis is associated with significantly decreased antral SLPI levels. The aim of the study was to investigate whether SLPI downregulation of gastric mucosa represents a specific phenomenon of H. pylori infection or is generally linked to gastric inflammation. Methods: SLPI expression was retrospectively analysed by immunohistochemistry in 85 paraffin-embedded samples: H. pylori-induced (n = 13), non-steroidal anti-inflammatory drug (NSAID)-enhanced (n = 18), autoimmune (n = 11), lymphocytic gastritis (n = 26) and H. pylori-negative controls (n = 17). The intensity of the staining was semiquantitatively analysed using an immunoreactivity score. Statistical analysis of differences was performed using an analysis of variance test. Results: In comparison with the control group, the SLPI expression of antral mucosa in H. pylori-mediated and lymphocytic gastritis was significantly lower (P",
keywords = "Autoimmune gastritis, Gastritis, Helicobacter pylori, Non-steroidal anti-inflammatory drug, Secretory leukocyte protease inhibitor",
author = "I. Hritz and Doerthe Kuester and Michael Vieth and L. Hersz{\'e}nyi and Manfred Stolte and Albert Roessner and Z. Tulassay and Thomas Wex and Peter Malfertheiner",
year = "2006",
month = "3",
doi = "10.1097/00042737-200603000-00008",
language = "English",
volume = "18",
pages = "277--282",
journal = "European Journal of Gastroenterology and Hepatology",
issn = "0954-691X",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Secretory leukocyte protease inhibitor expression in various types of gastritis

T2 - A specific role of Helicobacter pylori infection

AU - Hritz, I.

AU - Kuester, Doerthe

AU - Vieth, Michael

AU - Herszényi, L.

AU - Stolte, Manfred

AU - Roessner, Albert

AU - Tulassay, Z.

AU - Wex, Thomas

AU - Malfertheiner, Peter

PY - 2006/3

Y1 - 2006/3

N2 - Objectives: Secretory leukocyte protease inhibitor (SLPI) represents a multifunctional protein of the gastrointestinal mucosa exerting antimicrobial and anti-inflammatory effects. SLPI expression is generally induced during inflammation; however, Helicobacter pylori-meditated gastritis is associated with significantly decreased antral SLPI levels. The aim of the study was to investigate whether SLPI downregulation of gastric mucosa represents a specific phenomenon of H. pylori infection or is generally linked to gastric inflammation. Methods: SLPI expression was retrospectively analysed by immunohistochemistry in 85 paraffin-embedded samples: H. pylori-induced (n = 13), non-steroidal anti-inflammatory drug (NSAID)-enhanced (n = 18), autoimmune (n = 11), lymphocytic gastritis (n = 26) and H. pylori-negative controls (n = 17). The intensity of the staining was semiquantitatively analysed using an immunoreactivity score. Statistical analysis of differences was performed using an analysis of variance test. Results: In comparison with the control group, the SLPI expression of antral mucosa in H. pylori-mediated and lymphocytic gastritis was significantly lower (P

AB - Objectives: Secretory leukocyte protease inhibitor (SLPI) represents a multifunctional protein of the gastrointestinal mucosa exerting antimicrobial and anti-inflammatory effects. SLPI expression is generally induced during inflammation; however, Helicobacter pylori-meditated gastritis is associated with significantly decreased antral SLPI levels. The aim of the study was to investigate whether SLPI downregulation of gastric mucosa represents a specific phenomenon of H. pylori infection or is generally linked to gastric inflammation. Methods: SLPI expression was retrospectively analysed by immunohistochemistry in 85 paraffin-embedded samples: H. pylori-induced (n = 13), non-steroidal anti-inflammatory drug (NSAID)-enhanced (n = 18), autoimmune (n = 11), lymphocytic gastritis (n = 26) and H. pylori-negative controls (n = 17). The intensity of the staining was semiquantitatively analysed using an immunoreactivity score. Statistical analysis of differences was performed using an analysis of variance test. Results: In comparison with the control group, the SLPI expression of antral mucosa in H. pylori-mediated and lymphocytic gastritis was significantly lower (P

KW - Autoimmune gastritis

KW - Gastritis

KW - Helicobacter pylori

KW - Non-steroidal anti-inflammatory drug

KW - Secretory leukocyte protease inhibitor

UR - http://www.scopus.com/inward/record.url?scp=33644590993&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644590993&partnerID=8YFLogxK

U2 - 10.1097/00042737-200603000-00008

DO - 10.1097/00042737-200603000-00008

M3 - Article

C2 - 16462541

AN - SCOPUS:33644590993

VL - 18

SP - 277

EP - 282

JO - European Journal of Gastroenterology and Hepatology

JF - European Journal of Gastroenterology and Hepatology

SN - 0954-691X

IS - 3

ER -